Bayer continues to enhance its comprehensive radiology portfolio by advancing innovations in Artificial Intelligence (AI) and expanding its product pipeline. These advancements will be showcased at the 2024 Radiological Society of North America (RSNA) Annual Meeting from December 1–5 in Chicago.
At RSNA, Bayer will highlight seven new collaborations to expand its Calantic™ Digital Solutions platform, a medical imaging platform offering AI-powered applications. The company is also presenting new data on gadoquatrane, its investigational gadolinium-based contrast agent currently in Phase III development. Additionally, Bayer is unveiling its collaboration with Subtle Medical, a global med tech company focused on AI solutions.
Bayer’s MEDRAD® Centargo CT Injection System, recently cleared by the U.S. FDA, is another key product being showcased. This multi-patient CT injector helps automate tasks, reducing the burden on radiology technologists and allowing them to focus on patient care. With its smart injector capabilities and integration with workflow solutions, Centargo is designed to address the increasing demand for imaging and the shortage of radiology technologists, particularly in high-throughput settings.
In the field of AI, Bayer continues to drive innovation with its Calantic™ Digital Solutions platform. The platform, which integrates various third-party applications, aims to streamline radiology workflows by offering cloud-based solutions for tasks like lesion detection, prioritization, and reporting. Bayer is also extending its collaboration with leading AI providers, including Rad AI, AIRS Medical, Contextflow, Gleamer, and others, to expand its service offerings for clinical and operational AI applications.
In addition, Bayer’s AI Innovation Platform (AIIP), developed in collaboration with Google Cloud, is designed to accelerate the development, validation, and deployment of AI/ML healthcare applications. This cloud-based platform is already in testing, and it aims to empower developers in the healthcare sector to create scalable, compliant AI-powered imaging solutions.
At RSNA, Bayer will also present new clinical data on gadoquatrane, its investigational contrast agent for MRI. Two scientific sessions will highlight data on its pharmacokinetics and dose-response assessment, with one paper being honored with the prestigious Kuo York Chynn Neuroradiology Research Award.
Further demonstrating its commitment to AI in radiology, Bayer has announced an extended partnership with Subtle Medical to develop AI software in combination with a lower-dose contrast agent. This collaboration aims to optimize imaging solutions and enhance patient care.
As the global medical imaging AI market continues to grow, Bayer’s investments in AI and digital solutions position the company at the forefront of radiology innovation. Its portfolio of contrast media and AI-driven platforms aims to improve clinical workflows, enhance diagnostic accuracy, and support better patient outcomes.
